Related Experiment Video
Updated: Aug 1, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Therapeutic intervention with complement and beta-glucan in cancer
1Department of Pathology, University of Louisville, KY 40292, USA. gordon.ross@louisville.edu
Immunopharmacology
|July 17, 1999
Summary
Soluble yeast beta-glucan immunotherapy targets complement system resistance in tumor cells. This approach enables complement-mediated cell death and cytokine release, offering a novel cancer treatment strategy.
Area of Science:
- Immunology
- Complement System Biology
- Cancer Immunotherapy
Background:
- The complement system provides host defense via the Membrane Attack Complex (MAC) and C3 opsonization.
- MAC is ineffective against pathogens with cell walls; C3 opsonization enhances phagocytosis via CR3 receptors.
- Tumor cells possess natural resistance to MAC and CR3-mediated cytotoxic activation.
Purpose of the Study:
- To explore a novel immunotherapy using soluble yeast beta-glucan to overcome tumor cell resistance to complement-mediated attack.
- To investigate the mechanism by which beta-glucan enables the complement system's effector functions against cancer cells.
Main Methods:
- Review of complement system effector mechanisms and tumor cell resistance.
- Discussion of soluble yeast beta-glucan as an agent to modulate complement activation.
- Analysis of the interaction between beta-glucan, complement opsonization (iC3b), and CR3 receptor activation on immune cells.
Main Results:
- Soluble yeast beta-glucan overrides tumor cell resistance to CR3-mediated cytotoxicity.
- Beta-glucan-primed NK cells exhibit enhanced CR3 activation against iC3b-opsonized tumor cells.
- Tumor-localized secretion of cytokines (TNFα, IFNα, IFNγ, IL-6) accompanies beta-glucan-mediated immunotherapy.
Conclusions:
- Soluble yeast beta-glucan represents a promising strategy for cancer immunotherapy by reactivating complement effector mechanisms against tumors.
- This approach leverages the innate immune system to induce tumor cell death and anti-tumor cytokine production.
- The findings suggest a potential new therapeutic avenue for cancers resistant to conventional treatments.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
10:02Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...